Lithuania
Key Insights
- 1
No psychedelic therapy is approved for routine patient use in Lithuania; access remains limited to standard psychiatric medicines, with esketamine only appearing in research.
- 2
Lithuania shows just 4 trials, 0 active and 0 organisations, with esketamine and placebo the only compounds tracked in the database.
- 3
A notable marker: Lithuania has hosted multinational esketamine trials in Kaunas and Vilnius, including large placebo-controlled programmes registered on ClinicalTrials.gov.
- 4
Momentum is policy-led, not commercial: the 2023 National Agenda to 2035 and 2024 implementation plan prioritise drug-law reform and mental-health system upgrades.
Reimbursed Care Access
Most classical psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, mescaline, 2C‑X, ayahuasca) are controlled and not authorised for medical use in Lithuania outside of approved research. Ketamine is an established medical anaesthetic used in hospitals and is used off‑label in private clinics for depression; esketamine (Spravato) is registered in Lithuania but routine public reimbursement appears limited and treatment is typically delivered under specialist supervision or via private providers/clinics.
Quick Indicators
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Lithuania.